CA3236462A1 - Methods of treating agitation and other dementia-associated behavioral symptoms - Google Patents

Methods of treating agitation and other dementia-associated behavioral symptoms Download PDF

Info

Publication number
CA3236462A1
CA3236462A1 CA3236462A CA3236462A CA3236462A1 CA 3236462 A1 CA3236462 A1 CA 3236462A1 CA 3236462 A CA3236462 A CA 3236462A CA 3236462 A CA3236462 A CA 3236462A CA 3236462 A1 CA3236462 A1 CA 3236462A1
Authority
CA
Canada
Prior art keywords
fasudil
agitation
patient
dementia
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236462A
Other languages
English (en)
French (fr)
Inventor
Thomas Macallister
Sven Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3236462A1 publication Critical patent/CA3236462A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3236462A 2021-11-29 2022-11-15 Methods of treating agitation and other dementia-associated behavioral symptoms Pending CA3236462A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163283696P 2021-11-29 2021-11-29
US63/283,696 2021-11-29
PCT/US2022/079861 WO2023097151A1 (en) 2021-11-29 2022-11-15 Methods of treating agitation and other dementia-associated behavioral symptoms

Publications (1)

Publication Number Publication Date
CA3236462A1 true CA3236462A1 (en) 2023-06-01

Family

ID=86540411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236462A Pending CA3236462A1 (en) 2021-11-29 2022-11-15 Methods of treating agitation and other dementia-associated behavioral symptoms

Country Status (7)

Country Link
US (2) US20240423998A1 (cg-RX-API-DMAC10.html)
EP (1) EP4440566A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024544500A (cg-RX-API-DMAC10.html)
CN (1) CN118354769A (cg-RX-API-DMAC10.html)
CA (1) CA3236462A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024006505A (cg-RX-API-DMAC10.html)
WO (1) WO2023097151A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12329761B2 (en) * 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
WO2025024104A2 (en) * 2023-07-06 2025-01-30 Woolsey Pharmaceuticals, Inc. Method for reducing caregiver burden associated with alzheimer's disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104340D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
EP2061314A4 (en) 2006-08-10 2010-08-04 Translational Genomics Res Inst CONNECTIONS TO IMPROVE LEARNING AND MEMORY
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
CN101612157A (zh) 2008-06-26 2009-12-30 天津红日药业股份有限公司 法舒地尔诱导成年脑内源性神经干细胞再生的用途
EP2825175B1 (en) 2012-03-12 2017-07-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis
US9617214B2 (en) * 2013-11-08 2017-04-11 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
US10537567B2 (en) * 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
CN111050766A (zh) * 2017-07-21 2020-04-21 卡德门企业有限公司 Rho相关含卷曲螺旋蛋白激酶的抑制剂
EP3868408A4 (en) 2018-10-15 2022-07-06 National University Corporation Tokai National Higher Education and Research System ANTISYCHOTIC AND ITS USE
WO2021142183A1 (en) * 2020-01-09 2021-07-15 Woolsey Pharmaceuticals, Inc Methods of treating cortical dementia associated wandering
US11642352B2 (en) 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
CA3169944A1 (en) 2020-03-25 2021-09-30 Thomas Macallister Methods of using rho kinase inhibitors to treat frontotemporal dementia
US12329761B2 (en) * 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
WO2021257122A1 (en) 2020-06-15 2021-12-23 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat vascular dementia
EP4171564A4 (en) 2020-06-25 2024-06-26 Woolsey Pharmaceuticals, Inc. METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS
EP4181925A4 (en) 2020-07-14 2024-07-31 Woolsey Pharmaceuticals, Inc. METHODS OF TREATMENT OF PROTEINOPATHIES
US11311553B1 (en) 2020-10-22 2022-04-26 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies
US20220331333A1 (en) 2021-04-16 2022-10-20 Universite De Strasbourg Rhoa pathway inhibitor in the treatment of neurodevelopmental disorder or neuropsychiatric disorder
WO2022245708A1 (en) 2021-05-19 2022-11-24 Woolsey Pharmaceuticals, Inc. Methods of treating depression and anxiety
MX2023013538A (es) 2021-05-19 2023-11-27 Woolsey Pharmaceuticals Inc Metodos para tratar la depresion y la ansiedad.

Also Published As

Publication number Publication date
WO2023097151A1 (en) 2023-06-01
JP2024544500A (ja) 2024-12-03
MX2024006505A (es) 2024-06-05
EP4440566A4 (en) 2025-10-01
US11865119B2 (en) 2024-01-09
CN118354769A (zh) 2024-07-16
EP4440566A1 (en) 2024-10-09
US20230201219A1 (en) 2023-06-29
US20240423998A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
CA3073996C (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
US11865119B2 (en) Methods of treating agitation and other dementia-associated behavioral symptoms
JP2010511616A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
KR20140054129A (ko) 라퀴니모드와 인터페론-베타의 병용에 의한 다발성 경화증의 치료
US11311553B1 (en) Methods of treating 4-repeat tauopathies
CA3180411A1 (en) Methods of using rho kinase inhibitors to treat vascular dementia
EP4616909A2 (en) Methods of treating cortical dementia associated wandering
IL269550B1 (en) A combination of a 5ht3-antagonist and pramipexole for treating synucleinopathies
CA3189302A1 (en) Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
EP2766017B1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
EP4103187B1 (en) Fasudil for treating pseudobulbar affect
BR112021012491A2 (pt) Combinações antineurodegenerativas de domperidona e uso
JP2025087929A (ja) うつ病および／またはうつ状態の治療および／または予防用医薬
JP2025531623A (ja) タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法
Reuter et al. Lasmiditan hydrochloride
Guerra et al. Sinus tachycardia with paliperidone: a case report
CZ20021629A3 (cs) Farmaceutický prostředek
Dodd et al. Duloxetine for major depression
JP2017137306A (ja) トリプタンとアスコルビン酸を含有する医薬組成物
JP2009084253A (ja) 頭痛の予防および／または治療剤

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251023

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251023

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251023

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251031

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251110

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251222

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251222

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251222

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106